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Abstract 
Carbapenem-resistant Acinetobacter baumannii are the top urgent antibiotic resistance threat in the 
world. The aims of this study were the determination of carbapenem-resistant genes and virulence 
genes among isolates from hospital environments. In this study, A. baumannii isolated from hospital 
environments and evaluated its antibiotic resistance, virulence factors, and resistance genes. Of 258 
samples, 58 showed growth of the target organism. Antibiotic susceptibility test results considered all 
the A. baumannii to be multidrug-resistant isolates with the highest resistance being 36.2% to 
ciprofloxacin; while the most effective antibiotics with 98.3% susceptibility was piperacillin-
tazobactam. Of these 58 hospital environment isolates, 18 isolates were positive for Metallo beta-
lactamase. Overall, 65% of the isolates from hospital environments had many virulence factors. PCR 
assays demonstrated the highest and lowest positive results in csgA and cvaC gene among hospital 
environment isolates. Results indicate that the determination of carbapenem-resistant genes and 
virulence genes among isolates from hospital environments is very important. 
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1. Introduction 
Multidrug-resistant Acinetobacter baumannii is 
an opportunistic pathogen that causes nosocomial 
infections [1-3]. Infections caused by this bacterium 
have a high prevalence in hospitalized and 
immunocompromised patients who are admitted to 
intensive care units [4, 5]. These infections are 
ventilator-associated pneumonia, soft-tissue, urinary 
tract, and meningitis infections [6-8]. A. baumannii 
has an ability to survive for long periods the surfaces, 
sometimes even for several years [9]. Due to resistance 
to a broad range of antimicrobial agents can long-term 
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persistence in the clinical settings, surviving on 
nutrient sources and transmission by healthcare staff 
[10, 11]. 
Carbapenems and colistin are the last choices of 
antibiotic therapies against multi-drug resistant 
(MDR) A. baumannii strains [12]. The first 
carbapenem-resistant A. baumannii (CRAB) 
originated in the USA and was reported in 1991 [13]. 
Recent studies have reported that CRAB is a major 
causative organism in hospital-acquired infections 
[14]. Several mechanisms are responsible for 
resistance to carbapenems in CRAB [15]. The 
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production of carbapenemase enzymes is one of the 
important mechanisms of carbapenem resistance. 
These enzymes are class A, B, and D according to 
molecular Ambler classification. The members of class 
A carbapenemases include SME, IMI, NMC, GES, 
SFC, and KPC families. Also, class B enzymes are 
called metallo-beta-lactamases (MBLs), including 
IMP, VIM, SIM, and NDM. Class D β-lactamases 
referred to OXA-type enzymes or oxacillinases which 
are the most prevalent carbapenemases in A. 
baumannii [16, 17]. Prevalence of virulence Factors 
(VF) is contributed to pathogenesis in A. baumannii 
[18]. Some of the most significant VF of the A. 
baumannii strains are curli fibers (csg), colicin V 
production (cvaC), siderophores like aerobactin 
(iutA), and cytotoxic necrotizing factor (cnf) [18, 19]. 
The characterization of latent virulence genes, 
antimicrobial resistance, and molecular detection of 
carbapenemases of this bacterium in the hospital 
environments on abiotic and biotic surfaces are the 
important epidemiological issue. The aims of this 
study were the determination of antimicrobial 
resistance and molecular detection of antibiotic 
resistance and virulence genes among A. baumannii 
isolated from hospital environments in Qom hospitals. 
 
2. Materials and Methods 
2.1 Bacterial strain collection and identification 
The study was conducted at Pasteur Institute in 
the period from October 2019 to December 2019. 
Totally, 58 isolates were collected from different 
hospital environments of Qom hospitals (Kamkar and 
Beheshti hospitals) (Table 1). Samples were washed 
with PBS and transferred to brain heart infusion (BHI) 
media for further incubation at 37 °C. Samples were 
inoculated into blood agar and MacConkey agar for 
standard aerobic growth and placed at 37 °C 
overnight. The isolates were identified by the standard 
biochemical tests. The final confirmation of A. 
baumannii isolates was performed by PCR blaOXA-51-
like gene [20].  
 
2.2 Antimicrobial susceptibility testing 
According to the CLSI 2019 guidelines, the disk 
diffusion test was performed on Mueller-Hinton agar 
using a panel of nine antibiotic disks including 
ciprofloxacin (CIP), levofloxacin (LVX),  gentamicin 
(GM), imipenem (IMI), piperacillin-tazobactam 
(PTZ), ampicillin-sulbactam (SAM), ceftriaxone 
(CRO), and trimethoprim-sulfamethoxazole (SXT) 
(Mast Diagnostic, UK). 
 
2.3 Phenotypic detection of MBL production  
Combined disk diffusion test (CDDT) was 
performed using an imipenem disk (Mast Diagnostic, 
UK) and in combination with EDTA (Sigma, UK) to 
identify MBLs. The inhibition zones of the imipenem, 
and imipenem + EDTA disks were compared after 20 
h of incubation at 37 °C. In the combined disc test, if 
the increase in inhibition zone with the imipenem + 
EDTA disk was >7 mm than the imipenem disk alone, 
it was considered as MBL positive [21]. 
 
2.4 Detection of carbapenem resistance and 
virulence genes 
Genomic DNA extractions were performed based 
on the protocol as described elsewhere [22]. PCR 
reaction mixtures were prepared in total volumes of 25 
μl. The presence of the carbapenemase-encoding 
genes including blaOXA23-like, blaOXA24-like, blaOXA58-
like, blaIMP, blaNDM, and blaVIM genes and virulence 
genes cnf1, csgA, cvaC, iutA were investigated by PCR 
assays in all isolates [23-28]. All PCR primers are 













Sink 5.1% (3/58) 
Floor 6.8% (4/58) 
Pillow 12.0% (7/58) 
Desk 13.7% (8/58) 
Bed 3.4% (2/58) 
Under-bed wheels 8.6% (5/58) 
Door knob 12.0% (7/58) 
Nurses' fingers 5.1% (3/58) 
Walls 10.2% (6/58) 
Touchpads 22.4% (13/58) 
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3. Results  
Antibiotic susceptibility testing showed out of 58 
hospital environment isolated strains, the resistance 
against to CIP, LVX, GM, IMI, SXT, SAM, CRO, and 
PTZ were 36.2% (21/58), 31% (18/58), 18.9% (11/58), 
15.5% (9/58), 8.6% (5/58), 8.6% (5/58), 5.1% (3/58) 
and 1.7% (1/45), respectively. 
Of these 58 hospital environment isolates, 21/58 
(36.2%) showed resistance to imipenem and were 
therefore further tested for MBL production. Eighteen 
of these isolates showed positive results for MBL 
production by CDDT method as shown in Table 3. 
PCR analysis in all carbapenem-resistant isolates 
revealed that prevalence of blaVIM, blaOXA-23-like, 
blaOXA-24-like, and blaIMP were 10/21 (47.6%), 3/21 
(14.3%), 3/21 (14.3%), and 1/21 (4.7 %) of the strains, 
respectively. None of the hospital environment isolates 
carried blaOXA-58-like or blaNDM (Table 3). 
Also, PCR assays demonstrated positive results in 
43.1% (25/58) of strains for csgA, 32.7% (19/58) of 
strains for cnf1, 12% (7/58) of strains for iutA, and 
3.4% (2/58) of strains for cvaC genes among hospital 
environment isolates (Table 3). 
4. Discussion 
A. baumannii is an opportunistic pathogen and 
also has the ability to cause nosocomial diseases due to 
antibiotic resistance and can survive on surfaces, the 
body of the treatment staff, and patients [29, 30]. This 
bacterium has the ability to survive on different 
surfaces and objects, so it has a high potential for 
spread and colonization in hospitalized patients [31]. 
Through the mechanisms of acquisition of 
determinants of resistance and upregulation of 
intrinsic resistance mechanisms, this bacterium is able 
to resistance against a wide range of available 
antibiotics [30]. A. baumannii with multidrug 
resistance causes severe infections and high mortality, 
especially in patients with impaired immune systems 
or immunocompromised [2, 32]. Although the 
virulence factors and pathogenicity mechanism of A. 
baumannii are not fully understood and require 
further study and research, but this bacterium has the 
ability to cause a wide range of infections and deaths in 
hospitals. The virulence factors of this bacterium play 
an important role in resisting the host's defense 
mechanism [33, 34]. Also these factors are important 
 
Table 2. Primers used for amplification 
 













































F: Forward; R: Reverse 
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role in binding and invasion bacteria to host cells [28]. 
According to the contents, it is necessary to study the 
prevalence of antibiotic resistance and prepare a useful 
antibiotic treatment model to control and treat 
diseases caused by A. baumannii. The most important 
factor in resistance to carbapenem antibiotics is the 
presence of the 𝑏𝑙𝑎OXA genes, which causes the 
production of carbapenem hydrolyzing enzymes. In 
the present study, out of 58 isolates, the rate of 
antibiotic resistance in A. baumannii based on 
antibiotic susceptibility tests was the highest and 
lowest resistance for CIP and PTZ antibiotics, 
respectively. According to Nourbakhsh et al. (2018) 
studies, the highest resistance is related to CIP (97.2%) 
[35], which is similar to our study in terms of the 
highest antibiotic resistance. In the study of Shakibaie 
et al., resistance to CIP and PTZ was reported to be 
66% and 93.3%, respectively [36]. Although the 
 




MBL blaVIM blaOXA-23-like blaOXA-24-like blaIMP blaOXA-58-like blaNDM csgA cnf1 iutA cvaC 
1 - - - - - - - - + - - 
2 - - - - - - - + - - - 
3 - - - - - - - + + - - 
4 + + - - - - - - + - - 
5 - - - - - - - + - - - 
6 + - + - - - - + - - - 
7 + - - - - - - + + - - 
8 + + - - - - - + - - - 
9 - - - - - - - + + - + 
10 + + - - - - - + - - - 
11 - - - - - - - - + - - 
12 + - - + - - - + - - - 
13 - - - - - - - + - - - 
14 + + + - + - - + + - - 
15 - - - - - - - + - - - 
16 - - - - - - - + - - - 
17 + - - - - - - - + + - 
18 - - - - - - - - - + - 
19 + + - + - - - + + - - 
20 - - - - - - - - - + - 
21 - - - - - - - - - + - 
22 + - - - - - - + - - - 
23 - - - - - - - + + - - 
24 + - - - - - - + - - - 
25 + + - - - - - - + + - 
26 + - - - - - - + + - - 
27 - - - - - - - + - - - 
28 - - - - - - - + + - - 
29 - - - - - - - - + - - 
30 + + + - - - - + + - - 
31 + + - - - - - + - - - 
32 + + - - - - - + - - - 
33 - - - - - - - - + - - 
34 + - - - - - - + + - - 
35 - - - - - - - - - + - 
36 + + - + - - - + + - - 
37 - - - - - - - - - + - 
38 - - - - - - - - + - - 
39 – 58 - - - - - - - - - - - 
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bacterial resistance to CIP was as high as in our study, 
the resistance to PTZ differed greatly from our study. 
According to a study by Shirmohammadlou et al., A. 
baumannii is completely resistant to CIP [37], and this 
result is consistent with our study. These results are 
consistent with the study of Kabbaj et al., which 
showed that MBL production is among the 74% of 
bacteria resistant to imipenem [38].  
Among carbapenem-resistant isolates, the 
frequency of blaVIM and blaIMP genes had the highest 
and lowest, respectively. Also none of the hospital 
environment isolates carried blaOXA-58-like or blaNDM. In 
the study of Amudhan et al. [39], the most resistance 
is related to blaVIM in 45%, and in the study of 
Shirmohammadlou et al. [37], resistance to blaIMP was 
less common, which met with our study.  
Regard to prevalence of virulence genes, the 
results of our study were similar to those of Al-Kadmy 
et al. (Highest frequency was csgA 66.7% and lowest 
frequency was cvaC 9.5%) [40], Momtaz et al. 
(Highest frequency was csgA 55% and lowest 
frequency was cvaC 10%) [41], although our results 
contradicted the results of Darvishi study  (highest 
frequency was cnf1, 35.53% and lowest frequency was 
csgA 12.39%) [28]. 
The present study had some limitations. Mainly, 
this was a two-center study; therefore, the 
generalization of the results to other regions requires 
further investigations. 
In conclusion, increasing antibiotic resistance due 
to the acquisition of resistance genes and mutations 
due to selective pressures is a global problem. The 
increase in antibiotic resistance in A. baumannii is 
spreading, especially against effective antibiotics. 
Therefore, Studying and determining the pattern of 
antibiotic resistance for the preparation of a treatment 
protocol and the use of appropriate antibiotics is 
effective and reduces the increase in antibiotic 
resistance. In the current study, we isolated A. 
baumannii from hospital environments and 
determinated its antibiotic resistance, virulence factor, 
and resistance gene. Antibiotic susceptibility testing 
showed the most resistance and sensitivity was against 
CIP and PTZ respectively. PCR analysis in all 
carbapenem-resistant isolates revealed a high 
prevalence of blaVIM and blaIMP. Also, results 
demonstrated the highest and lowest positive results 
for csgA and cvaC gene among hospital environment 
isolates. 
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